Teva, Sanofi Say Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

MT Newswires Live12-17

Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals and Sanofi (SNY) said Tuesday that a phase 2b study on duvakitug met primary endpoints in patients with ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease.

The companies said 47.8% of ulcerative colitis patients treated with high-dose duvakitug achieved clinical remission at week 14 and 47.8% of Crohn's disease patients on high-dose duvakitug achieved endoscopic response.

Duvakitug was well tolerated, with adverse event rates similar between treatment and placebo groups, the companies added.

Teva and Sanofi said they plan to initiate a phase 3 trial after regulatory discussions. Detailed results of the phase 2b trial are expected to be presented in 2025, they added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492957101?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492957101","market":"sg","top_or_hot":-1,"title":"Teva, Sanofi Say Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease","media":"MT Newswires Live","content":"<html><body><p> Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals and <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Tuesday that a phase 2b study on duvakitug met primary endpoints in patients with ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease.</p><p>The companies said 47.8% of ulcerative colitis patients treated with high-dose duvakitug achieved clinical remission at week 14 and 47.8% of Crohn's disease patients on high-dose duvakitug achieved endoscopic response.</p><p>Duvakitug was well tolerated, with adverse event rates similar between treatment and placebo groups, the companies added.</p><p>Teva and Sanofi said they plan to initiate a phase 3 trial after regulatory discussions. Detailed results of the phase 2b trial are expected to be presented in 2025, they added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva, Sanofi Say Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva, Sanofi Say Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 21:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals and Sanofi (SNY) said Tuesday that a phase 2b study on duvakitug met primary endpoints in patients with ulcerative colitis and ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492957101","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492957101","pubTimestamp":1734442998,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries'  US affiliate Teva Pharmaceuticals and Sanofi  said Tuesday that a phase 2b study on duvakitug met primary endpoints in patients with ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease.The companies said 47.8% of ulcerative colitis patients treated with high-dose duvakitug achieved clinical remission at week 14 and 47.8% of Crohn's disease patients on high-dose duvakitug achieved endoscopic response.Duvakitug was well tolerated, with adverse event rates similar between treatment and placebo groups, the companies added.Teva and Sanofi said they plan to initiate a phase 3 trial after regulatory discussions. Detailed results of the phase 2b trial are expected to be presented in 2025, they added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4557":"大麻股","TEVA":"梯瓦制药","SNYNF":"Sanofi","BK4585":"ETF&股票定投概念","SNY":"赛诺菲安万特","BK4559":"巴菲特持仓","BK4566":"资本集团","BK4596":"哈里斯概念","BK4588":"碎股","BK4007":"制药","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC"},"translate_title":"梯瓦和赛诺菲表示2B期Duvakitug研究达到炎症性肠病的主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"SNY":0.9,"TEVA":0.9},"content_text":"Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals and Sanofi (SNY) said Tuesday that a phase 2b study on duvakitug met primary endpoints in patients with ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease.The companies said 47.8% of ulcerative colitis patients treated with high-dose duvakitug achieved clinical remission at week 14 and 47.8% of Crohn's disease patients on high-dose duvakitug achieved endoscopic response.Duvakitug was well tolerated, with adverse event rates similar between treatment and placebo groups, the companies added.Teva and Sanofi said they plan to initiate a phase 3 trial after regulatory discussions. Detailed results of the phase 2b trial are expected to be presented in 2025, they added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492957101"}